Psychopharmacology at Depression Clinical and Research Program, MGH
Psychiatry
Dr. David Mischoulon, MD
|
|
Give Review
David Mischoulon is an expert in the field of Psychiatry. He went to Boston University School of Medicine. Boston University School of Medicine is ranked 30 in research and 52 in primary care medicine David Mischoulon is a published doctor as well. He has 100 publications published. The latest was: Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation. He accepts Medicare.
Publications
- Anxiety symptoms are linked to new-onset suicidal ideation after six months of follow-up in outpatients with major depressive Disorder.
- Efficacy and safety of a form of cranial electrical stimulation (CES) as an add-on intervention for treatment-resistant major depressive Disorder: A three week double ...
- Efficacy of ziprasidone monotherapy in patients with anxious depression: A 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial.
- Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive Disorder: a proof-of-concept study.
- Association between physician beliefs regarding assigned treatment and clinical response: Re-analysis of data from the Hypericum Depression Trial Study Group.
- A Double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive Disorder.
- Sleep Quality, PostTraumatic Stress, Depression, and Human Errors in Train Drivers: A Population-Based Nationwide Study in South Korea.
- A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression.
- S-adenosyl methionine (SAMe) versus escitalopram and placebo in Major depression RCT: Efficacy and effects of histamine and carnitine as moderators of response.
- Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive Disorder: a 12-week, randomized, double-blind, placebo-control...
- Improvement in Subjective and Objective Neurocognitive Functions in Patients With Major Depressive Disorder: A 12-Week, Multicenter, Randomized Trial of Tianeptine Ver...
- What is the Role of Alternative Treatments in Late-life Depression?
- Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John's Wort in Major Depressive Disorder.
- The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.
- Building an evidence base in complementary and integrative healthcare for child and adolescent psychiatry.
- Childhood Parental Death and Lifetime Suicide Attempt of the Opposite-Gender Offspring in a Nationwide Community Sample of Korea.
- RELATIONSHIP BETWEEN SLEEP DISTURBANCE AND DEPRESSION, Anxiety, AND FUNCTIONING IN COLLEGE STUDENTS.
- Differential impact of isolated psychotic symptoms on treatment outcome of major depressive Disorder in the STAR*D cohort of Whites, Blacks and Latinos.
- Delayed Amnesic Syndrome after Riluzole Use in Major Depressive Disorder: A Case Report.
- The effect of sildenafil on quality of life.
- A pilot study of acupuncture monotherapy in patients with major depressive Disorder.
- A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive Disorder.
- A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive Disorder and alcohol use Disorder.
- Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive Disorder.
- SAMe and sexual functioning.
- Acupuncture for depression: a review of clinical applications.
- Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive Disorder, and their impact on response to fluoxetine treatment.
- Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive Disorder.
- A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepress...
- The impact of omega-3 fatty acids on depressive Disorders and suicidality: can we reconcile 2 studies with seemingly contradictory results?
- Comparison of academic and nonacademic sites in multi-center clinical trials.
- Can you recommend anything for dysthymia?
- What is maca root?
- Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group.
- Adjunctive nutraceuticals with standard pharmacotherapies in bipolar Disorder: a systematic review of clinical trials.
- Omega-3 for bipolar Disorder: meta-analyses of use in mania and bipolar depression.
- Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire.
- A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females.
- The treatment of minor depression with St. John''s Wort or citalopram: failure to show benefit over placebo.
- Do early changes in the HAM-D-17 Anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St ...
- A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
- Atypical psychotic symptoms in a Hispanic population: diagnostic dilemmas and implications for treatment.
- Evidence for folate in combination with antidepressants at initiation of therapy.
- Depression and eating Disorders: treatment and course.
- Psychoticism and paranoid ideation in patients with nonpsychotic major depressive Disorder: prevalence, response to treatment, and impact on short- and long-term treat...
- A pilot study of acupuncture augmentation therapy in antidepressant partial and non-responders with major depressive Disorder.
- Early improvements in Anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
- S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive Disorder: a double-blind, randomized ...
- Second-tier natural antidepressants: review and critique.
- Complementary and alternative medicine for major depressive Disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relati...
- Complementary and alternative medicine in major depressive Disorder: the American Psychiatric Association Task Force report.
- Anxious depression and early changes in the HAMD-17 Anxiety-somatization factor items and antidepressant treatment outcome.
- Low-dose transdermal testosterone augmentation therapy improves depression severity in women.
- Deficits in psychological well-being and quality-of-life in minor depression: implications for DSM-V.
- Update and critique of natural remedies as antidepressant treatments.
- Folate in depression: efficacy, safety, differences in formulations, and clinical issues.
- The status of nutraceuticals for the treatment of depression.
- Report of two double-blind randomized placebo-controlled pilot studies of a carbohydrate-rich nutrient mixture for treatment of seasonal affective Disorder (SAD).
- A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive Disorder.
- Frontal EEG predictors of treatment outcome in major depressive Disorder.
- Are nutritional supplements ready for prime time?
- A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction.
- Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive Disorder.
- Clinical features and functioning of patients with minor depression.
- Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression.
- A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive Disorder.
- Acupuncture for major depressive Disorder: has its efficacy been disproved?
- The role of folate in depression and dementia.
- Does psychiatry residency training reflect the "real world" of psychiatry practice? A survey of residency graduates.
- Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry.
- Dysfunctional attitudes and personality Disorder comorbidity during long-term treatment of MDD.
- Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis.
- The combination of duloxetine and bupropion for treatment-resistant major depressive Disorder.
- Outcomes of recognizing depressed Chinese American patients in primary care.
- Anger attacks in major depressive Disorder and serum levels of homocysteine.
- Relationships between major depressive Disorder and comorbid anxiety and personality Disorders.
- A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive Disorder.
- An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive Disorder.
- The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive Disorder and the timing of improvement with fluoxetine.
- The relationship between early changes in the HAMD-17 Anxiety/somatization factor items and treatment outcome among depressed outpatients.
- The overlap between personality Disorders and major depressive Disorder (MDD).
- S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive Disorder: an open trial following partial or nonresponse to selective serotonin reuptake in...
- The potential relationship between levels of perceived stress and subtypes of major depressive Disorder (MDD).
- Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and p...
- Serum folate, vitamin B12, and homocysteine in major depressive Disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy.
- Serum folate, vitamin B12, and homocysteine in major depressive Disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression.
- Integrating psychiatry and primary care improves acceptability to mental health services among Chinese Americans.
- "The Matrix": An allegory of the psychoanalytic journey.
- Cholesterol in mood and anxiety Disorders: review of the literature and new hypotheses.
- A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive Disorder: comparing patients who recently discontinued an SSRI with th...
- Prevalence of major depressive Disorder among Chinese-Americans in primary care.
- Quality of life assessments in major depressive Disorder: a review of the literature.
- Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day.
- Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment.
- Serum cholesterol and serotonergic function in major depressive Disorder.
- The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists.
- Functioning and interpersonal relationships as predictors of response in treatment-resistant depression.
- Loss of sexual interest and premenstrual mood change in women with postpartum versus non-postpartum depression: A nationwide community sample of Korean adults.
- Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
Schools
Boston University School Of Medicine
Caritas Carney Hospital
Massachusetts General Hospital
Procedures Preformed
- Group Psychotherapy
- Psychiatric Evaluation
- Psychological Testing
- Psychotherapy and Psychophysiological Therapy (incl. Biofeedback)
Conditions Treated
- Adjustment Disorder
- Anxiety
- Borderline Personality Disorder
- Dissociative, Conversion, and Factitious Disorders
- View All
Doctors Specialties
- Psychiatry
Accepted Insurances
Education
-
Massachusetts General Hospital -
Boston University School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1841286887 | |
| NPPES Provider LastName | MISCHOULON | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 021143117 | |
| NPPES Provider State | MA | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 585.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1841286887 |
| Last Name Of The Provider | MISCHOULON |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Betty C. Wang, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ginger Chappell, PHD |
|
|
Dr. Osarumen N. Nomamiukor, MD |
|
|
Dr. Deborah R. Friedman, PHD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward F. Rabe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jane T. Schwartz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leena P. Mittal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew A. Nierenberg, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Violeta C. Valdivia, MD |